转铁蛋白受体单抗WuT_9导向治疗晚期肝癌

Bio-Targeting Immunotherapy for Advanced Hepatocellular Carcinoma Using Monoclonal Anti-transferrin Receptor Antibody WuT_9 as Carrier

应用转铁蛋白受体单抗ＷｕＴ_９对晚期肝癌进行了临床研究；４例进行了放射免疫显像检查，２２例进行了临床治疗观察。结果表明：①４例显像检查病人中，有３例肿瘤于注射^（１３１）ＩＷｕＴ_９偶联物后第７天呈清楚显像；②２２例接受阿霉素－ＷｕＴ_９偶联物治疗后，近期疗效观察：１８例有效，７例显效；远期随访２年者１５例，４例存活，其中２例存活已４年；对照组１０例，有效仅３例，无显效，无１例存活２年。

Using￣(131)I-labelled monoclonal anti-transferrin receptor antibody WuT_9 and the conjugate of the antibody with adriamycin, radioimmunoimaging in 4 cases of HCC patients and bio-targeting immunotherapy in 22 cases of advanced HCC patients were investigated,respectively. The results showed that clear imaging of tumors was obtained in 3 out of 4 patients and that the conditions of 18 patients were improved. 7 of them were markedly improved.The efficacy of the therapy was enhanced when combined with transcatheter arterial embolization with minimal side effects. Fifteen patients have been followed up for 2 years with 4 patients still surviving,2 of them having survived for 4 years. Thus,we may reach the conclusion that the bio-targeting immunotherapy using WuT_9 as carrier may become a new promising strategy for comprehensive treatment of HCC.